Insulin Treatment Attenuates Small Nerve Fiber Damage in Rat Model of Type 2 Diabetes

Table 1

Glycemic control, circulating lipids, and body composition before treatment initiation and at study termination.

	Control	STZ-DIO vehicle	STZ-DIO low-insulin	STZ-DIO high-insulin	Overall value; (ANOVA)
Glycemic control and circulating lipids
Average blood glucose (mM)	^A	^B	^C	^D	<0.001
HbA1c (%)
Pretreatment	^A	^B	^B	^B	<0.001
Posttreatment	^A	^B	^B	^C	<0.001
C-peptide (pM)
Pretreatment	^A	^B	^B	^B	<0.001
Posttreatment	^A	^B	^B	^B	<0.001
Human insulin (pM)
Posttreatment	^A	^A	^B	^C	<0.001
Triglyceride (mM)
Pretreatment	^A	^B	^B	^B	<0.001
Posttreatment	^A	^B	^C	^C	<0.001
Total cholesterol (mM)
Pretreatment	^A	^B	^B	^B	<0.001
Posttreatment	^A	^B	^C	^C	<0.001
Body composition
Body weight (g)
Pretreatment	^A	^A	^A	^A	0.3
Posttreatment	^AB	^A	^B	^C	<0.001
Body fat percentage (%)
Pretreatment	^A	^A	^A	^A	0.8
Posttreatment	^AB	^A	^B	^C	<0.001

Data are presented as mean and SD. Group differences tested by one-way ANOVA followed by a post hoc test with the Tukey-Kramer adjusted values. Values sharing the same superscript letter are not statistically different. Nonparametric analysis.